Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Chugai Pharma (4519 JP): Guidance Reiterated As Both Overseas & Domestic Grow in 1H26

Chugai Pharma (4519 JP): Hemlibra, Actemra Hold the Show Together, Orforglipron Is The Next Big Draw

Chugai Pharmaceutical (4519 JP): Actemra Shine Bright Amid Margin Pressure, 2025 Guidance Reiterated

Chugai Pharma (4519 JP): Hemlibra Steady, Actemra Shine, Outlicensed Drug and New Launches Key

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/chugai-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:4489:1" rel="noopener">Chugai Pharmaceutical (4519 JP)</a> reported a rise of 11.5% YoY in revenue to ¥321.7B. Hemlibra overseas sales stood at ¥108.9B (37% of total sales), up 26% YoY.</li>
<li>2026 guidance reiterated. Revenue is expected to increase to ¥1,345B (up 7% YoY). Both core operating profit and core net income expected to increase by 7.5% YoY each.</li>
<li>Eli Lilly received the U.S. FDA approval for Founday (orforglipron) for adults with obesity and it has been launched in the US market in early April 2026.</li>
</ul>



Chugai Pharmaceutical (4519 JP) reported a rise of 11.5% YoY in revenue to ¥321.7B. Hemlibra overseas sales stood at ¥108.9B (37% of total sales), up 26% YoY.
2026 guidance reiterated. Revenue is expected to increase to ¥1,345B (up 7% YoY). Both core operating profit and core net income expected to increase by 7.5% YoY each.
Eli Lilly received the U.S. FDA approval for Founday (orforglipron) for adults with obesity and it has been launched in the US market in early April 2026.


Chugai Pharma (4519 JP): Hemlibra Drive 1Q26, 2026 Guidance Reiterated, Orforglipron Launched in US